BIOS — Biosenic SA Income Statement
0.000.00%
Last trade - 00:00
- €3.83m
- €26.80m
2018 December 31st | R2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 1 | 0 | 1 | 1 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 12.5 | 7.95 | 16 | 13 | 2.32 |
Operating Profit | -11.5 | -7.95 | -15 | -12 | -2.32 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -14 | -7.52 | -15.8 | -12.8 | -3.05 |
Provision for Income Taxes | |||||
Net Income After Taxes | -14.1 | -7.52 | -15.8 | -12.9 | -3.05 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -14.2 | -10.5 | -11.9 | -12.9 | -2.04 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -14.2 | -10.5 | -11.9 | -12.9 | -2.04 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -1.87 | -0.802 | -1.35 | -0.767 | -0.017 |
Dividends per Share |